"Molecular imaging today allows physicians to make decisions with greater insight, precision and confidence, bringing healthcare one step closer to personalized care," said Kirill Shalyaev, Ph.D., Business Leader, Advanced Molecular Imaging, Philips. "Philips has made a lasting impact in nuclear medicine by providing clinicians with innovations such as Time-of-Flight PET and digital PET/CT, and we remain dedicated to developing solutions that simplify the path to clinical decision making for more confident diagnosis and a faster path to treatment."

Even with its significant growth in past years, the opportunity for further innovation and growth in nuclear medicine remains, continuing to maximize its value and impact. Philips' SNMMI exhibit (booth 657) will feature the company's latest solutions and technologies driving the future of nuclear medicine:

Innovation Talks This year, Philips will host a number of talks and presentations at its booth (#657) at SNMMI. In addition, Philips' academic partners will present 19 scientific presentations and posters demonstrating the value Philips' digital PET/CT system is bringing to molecular imaging advancing knowledge and application using features such as lesion detection and quantitative imaging.

For more information on Philips' molecular imaging solutions, and to learn more about the company's presence at SNMMI 2017, visit booth 657, http://www.philips.com/snmmi and follow the conversation on@PhilipsLiveFrom.

For further information, please contact: Alicia CafardiPhilips Group CommunicationsTel: + 1 412-523-9616E-mail: alicia.cafardi@philips.com

About Royal PhilipsRoyal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 70,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.comnewscenter.

[1] Nguyen NC,Image Quality and Diagnostic Performance of a Digital PET Prototype in Patients with Oncologic Diseases: Initial Experience and Comparison with Analog PET, J Nucl Med 2015; 56:13781385.[2] Liu X et al, Impact of FDG Dose Reduction on Lesion Quantification in Dynamic PET: A Simulation Study Based on Clinical Trial Data, SNMMI 2016.[3] Zhang J., Evaluation of speed of PET acquisition: How fast can we go? - A validation of list mode PET simulation approach with true acquisitions, SNMMI 2017.

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/philips-highlights-the-value-of-advanced-molecular-imaging-at-snmmi-2017-300472014.html

SOURCE Royal Philips

Original post:

Philips highlights the value of advanced molecular imaging at SNMMI 2017 - PR Newswire (press release)